MedTrace Logo

Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study

NCT06651580 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1600

Last updated 2026-03-04

No results posted yet for this study

Summary

This clinical trial collects blood, saliva, urine, or stool samples to help identify possible genetic mutations that may increase a person's chance at developing pancreatic cancer. Finding genetic markers among pediatric patients with acute recurrent pancreatitis and chronic pancreatitis may help identify patients who are at risk of pancreatic cancer.

Conditions

  • Chronic Pancreatitis
  • Exocrine Pancreas Carcinoma
  • Recurrent Acute Pancreatitis

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of blood, saliva, urine or stool samples

OTHER

Quality-of-Life Assessment

Complete QoL assessment

OTHER

Questionnaire Administration

Complete questionnaire

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Ying Yuan, PHD · M.D. Anderson Cancer Center

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2027-02-02
Completion
2027-02-02

Countries

  • United States
  • Australia
  • Canada
  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06651580 on ClinicalTrials.gov